+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Antibody Drug Conjugate"

From
Peptide Therapeutics Market - Global Forecast to 2036 - Product Thumbnail Image

Peptide Therapeutics Market - Global Forecast to 2036

  • Report
  • September 2026
  • 310 Pages
  • Global
From
From
Precision Oncology Market - Global Forecast to 2036 - Product Thumbnail Image

Precision Oncology Market - Global Forecast to 2036

  • Report
  • March 2026
  • 288 Pages
  • Global
From
Immunotherapy Platforms Market - Global Forecast to 2036 - Product Thumbnail Image

Immunotherapy Platforms Market - Global Forecast to 2036

  • Report
  • March 2026
  • 320 Pages
  • Global
From
From
From
Disposable Flow-Battery Bioreactor Market Report 2026 - Product Thumbnail Image

Disposable Flow-Battery Bioreactor Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
From
Hormone-Refractory Oncology Drug Market Report 2026 - Product Thumbnail Image

Hormone-Refractory Oncology Drug Market Report 2026

  • Report
  • July 2026
  • 250 Pages
  • Global
From
Loading Indicator

The Antibody Drug Conjugate (ADC) market is a subset of the biotechnology industry that focuses on the development of targeted therapies for cancer and other diseases. ADCs are composed of an antibody, a linker, and a cytotoxic drug. The antibody binds to a specific target on the surface of a cell, and the linker and drug are released when the ADC binds to the target. This allows for the delivery of a high dose of the drug to the target cell, while minimizing the damage to healthy cells. ADCs have been used to treat a variety of cancers, including breast, ovarian, and non-small cell lung cancer. They have also been used to treat other diseases, such as autoimmune disorders and infectious diseases. The ADC market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Seattle Genetics, ImmunoGen, Pfizer, Merck, and Novartis. Show Less Read more